Oncopeptides AB (publ) (STO:ONCO)

Market Cap	1.30B
Revenue (ttm)	39.84M
Net Income (ttm)	-277.57M
Shares Out	225.76M
EPS (ttm)	-1.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,325,625
Average Volume	11,462,624
Open	5.97
Previous Close	6.15
Day's Range	5.75 - 6.12
52-Week Range	1.10 - 6.96
Beta	-0.60
RSI	67.65
Earnings Date	Aug 21, 2025

About ANSYS

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hyd...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 80
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ONCO

Financial Performance

In 2024, Oncopeptides AB's revenue was 31.65 million, a decrease of -10.14% compared to the previous year's 35.22 million. Losses were -284.61 million, 14.2% more than in 2023.